Running hot in customers' hands: existing deployments are being used harder than they were sized for
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了现有客户对产品/服务的使用强度高于原计划,且这种更重的使用是当前可观察到的现象。 在记录中,管理层提到: - “We continue to see robust growth in the translational markets with growing momentum within our biopharma and CRO partners as they leverage the PhenoImager HT platform to address their growing biomarker needs” - “we are seeing encouraging results of our emphasis on driving reagent growth. The annualized second quarter reagent pull-through has now increased to the mid-$30,000 range for both the PhenoCycler and HT” - “as we see increasing utility of HT among biopharma and CROs” - “we anticipate annual reagent revenue growth to be in this range for the next several years” (但这是预期) - 关于Fusion 2.0升级,提到“field upgrades started with our first customers in June and we expect a significant percentage of our PhenoCycler-Fusion customers to upgrade by year-end” 但这是未来计划。 - 关于HT改进,“In July, we introduced improvements to the HT that moves post-processing and tissue analysis workflow directly on to the HT for on instrument and real-time compute. This results in a severalfold reduction in both image processing and turnaround time” 但这是新改进,尚未体现为现有客户更重使用。 关键点:管理层提到“annualized second quarter reagent pull-through has now increased to the mid-$30,000 range” 相比2022年的低$30,000,这表示每个仪器的年化试剂消耗增加了,这可以视为现有客户使用强度增加。但这是否是“比原计划更重”?管理层说“as we see increasing utility of HT among biopharma and CROs”,这似乎是观察到的现象。但增长幅度不大(从低30k到中30k),且没有明确说“超出预期”或“比计划更重”。另外,管理层强调“we are seeing encouraging results of our emphasis on driving reagent growth”,这可能是公司推动的结果,而非客户自发超预期使用。 此外,管理层提到“we anticipate annual reagent revenue growth to be in this range for the next several years” 这是预期,不是当前观察。 关于服务收入增长73%,但那是由于安装基数扩大和保修收入,以及实验室服务,并非单客户使用强度。 总体来看,管理层没有明确描述现有客户的使用强度超出原计划,而是说“increasing utility”和“pull-through increased”,但这是公司推动的结果,且幅度不大。没有提到客户“exhausting”或“outgrowing”等。因此,我认为答案应为NO。 最终回答:NO
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| APYX | Apyx Medical Corporation | Q4 2023 | 2024-03-21 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
TJX · Q2 2021 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...
WES · Q3 2018 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...
BCE · Q2 2017 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...